Results 91 to 100 of about 20,698 (251)
Semaglutide: First Global Approval
, 2018 Compliance with Ethical StandardsFunding: The preparation of this review was not supported by any external funding.Conflicts of interest: During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on ...
Sohita Dhillon, Sohita Dhillon (4873375)
core +1 more source
Gut microbiota dysbiosis in the inflammatory pathogenesis of diabetic retinopathy
VIEW, EarlyView.This graphical abstract illustrates how gut dysbiosis drives diabetic retinopathy through the gut‐retina axis, a process unfolding in three interconnected stages. First, in the gut, a decrease in beneficial bacteria and an increase in pro‐inflammatory taxa compromise the intestinal barrier, causing a “leaky gut” that allows LPS to translocate into the ...
Junyan Hu, Jingxiang Zhong
wiley +1 more source
Anti‐obesity medications and incident ocular outcomes: A systematic review and network meta‐analysis
VIEW, EarlyView.In this systematic review and network meta‑analysis of 140 studies, anti‑obesity medications showed heterogeneous ocular safety profiles. Semaglutide was associated with higher NAION risk (observational data), whereas dual/multi‑agonists and glucagon‐like peptide‐1 receptor agonists demonstrated favourable glaucoma and overall ocular outcomes ...
Linge Jian +5 more
wiley +1 more source
Contractile Effects of Semaglutide in the Human Atrium
PharmaceuticsSemaglutide is a glucagon-like peptide 1 receptor (GLP-1R) agonist. GLP-1R agonists are used to treat type 2 diabetes and obesity. It is currently unknown whether semaglutide can directly increase force of contraction (FOC) in the human heart.
Joachim Neumann +4 more
doaj +1 more source
Effectiveness and Safety of Weekly Subcutaneous Semaglutide for Weight Management in Obese Adolescents: An Observational Study [PDF]
[eng] We aimed to evaluate effectiveness and safety of weekly subcutaneous (sc) semaglutide for weight reduction, along with diet and lifestyle modifications in severely obese adolescent patients attending an Obesity Unit.
Tofé, S. +3 more
core
Glucagon‐like peptide‐1 receptor agonist use and violent crime among US adults
Criminology, EarlyView.Abstract Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), a class of medications widely prescribed for diabetes and obesity, have exhibited emerging effects on substance use, reward processing, and impulse control. This study examines whether current GLP‐1 RA use moderates established behavioral pathways to violent crime from impulsivity and ...
Daniel C. Semenza, Christopher Thomas
wiley +1 more source
Mei Liu,1,* Sili Guo,1,* Xiaohan Li,1,* Yang Tian,1 Yanjie Yu,2 Lili Tang,1 Qimei Sun,1 Ting Zhang,1 Mingwei Fan,3 Lili Zhang,1 Yingjiang Xu,4 Jiajia An,5 Xiangqian Gao,6 Lei Han,7 Lei Zhang1 1Department of Endocrinology and Metabolism ...
Liu M +13 more
core
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality. [PDF]
IMPORTANCE Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have gained use primarily due to their weight-reduction effects, although a regulatory review was undertaken for potential suicidality concern.
Barbui, Corrado +4 more
core +2 more sources
Beyond abstinence: Redefining success in cannabis use disorder treatment
Addiction, EarlyView.Abstract Background Over two decades of pharmacotherapy research has yet to yield a consistently effective medication for cannabis use disorder (CUD), in part because clinical trials have frequently prioritized abstinence as a primary or key endpoint.
Tobias B. Atkin +3 more
wiley +1 more source
Semaglutide improves metabolic dysfunction‐associated steatohepatitis: A 10‐year retrospective study
JGH OpenBackground and Aims Semaglutide has been studied in patients with metabolic dysfunction‐associated steatohepatitis (MASH) due to potential benefit from weight loss on liver inflammation.
Parth Shah +7 more
doaj +1 more source